Charles Schwab’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $32.7M | Sell |
703,552
-2,424
| -0.3% | -$116K | ﹤0.01% | 1516 |
|
|
2026
Q1 | $36.5M | Buy |
705,976
+2,351
| +0.3% | +$120K | 0.01% | 1374 |
|
|
2025
Q4 | $35M | Sell |
703,625
-28,864
| -4% | -$1.4M | 0.01% | 1391 |
|
|
2025
Q3 | $35M | Sell |
732,489
-16,152
| -2% | -$650K | 0.01% | 1382 |
|
|
2025
Q2 | $23.6M | Buy |
748,641
+2,492
| +0.3% | +$79.9K | ﹤0.01% | 1580 |
|
|
2025
Q1 | $24.4M | Sell |
746,149
-7,214
| -1% | -$256K | ﹤0.01% | 1525 |
|
|
2024
Q4 | $27.2M | Buy |
753,363
+40,968
| +6% | +$1.44M | 0.01% | 1517 |
|
|
2024
Q3 | $22.2M | Buy |
712,395
+91,354
| +15% | +$2.85M | ﹤0.01% | 1638 |
|
|
2024
Q2 | $16.6M | Buy |
621,041
+28,395
| +5% | +$823K | ﹤0.01% | 1787 |
|
|
2024
Q1 | $20.2M | Buy |
592,646
+36,716
| +7% | +$1.09M | ﹤0.01% | 1603 |
|
|
2023
Q4 | $16.1M | Buy |
555,930
+24,684
| +5% | +$654K | ﹤0.01% | 1719 |
|
|
2023
Q3 | $14.6M | Sell |
531,246
-11,262
| -2% | -$343K | ﹤0.01% | 1698 |
|
|
2023
Q2 | $16.3M | Buy |
542,508
+32,702
| +6% | +$1.14M | ﹤0.01% | 1630 |
|
|
2023
Q1 | $18.5M | Buy |
509,806
+2,355
| +0.5% | +$90.6K | 0.01% | 1531 |
|
|
2022
Q4 | $18.1M | Buy |
507,451
+39,677
| +8% | +$1.38M | 0.01% | 1511 |
|
|
2022
Q3 | $15.8M | Buy |
467,774
+38,323
| +9% | +$1.25M | 0.01% | 1547 |
|
|
2022
Q2 | $12.4M | Buy |
429,451
+27,161
| +7% | +$778K | ﹤0.01% | 1723 |
|
|
2022
Q1 | $13M | Buy |
402,290
+33,198
| +9% | +$1.02M | ﹤0.01% | 1804 |
|
|
2021
Q4 | $10.8M | Buy |
369,092
+7,087
| +2% | +$215K | ﹤0.01% | 1964 |
|
|
2021
Q3 | $9.65M | Sell |
362,005
-56,535
| -14% | -$1.52M | ﹤0.01% | 2032 |
|
|
2021
Q2 | $12.9M | Sell |
418,540
-32,389
| -7% | -$993K | ﹤0.01% | 1869 |
|
|
2021
Q1 | $11.8M | Buy |
450,929
+11,432
| +3% | +$320K | ﹤0.01% | 1855 |
|
|
2020
Q4 | $11.1M | Sell |
439,497
-7,217
| -2% | -$155K | ﹤0.01% | 1802 |
|
|
2020
Q3 | $9.31M | Buy |
446,714
+103,632
| +30% | +$2.35M | ﹤0.01% | 1748 |
|
|
2020
Q2 | $8.15M | Buy |
343,082
+22,938
| +7% | +$507K | ﹤0.01% | 1770 |
|
|
2020
Q1 | $5.76M | Sell |
320,144
-85,224
| -21% | -$1.79M | ﹤0.01% | 1765 |
|
|
2019
Q4 | $9.62M | Buy |
405,368
+6,320
| +2% | +$153K | 0.01% | 1689 |
|
|
2019
Q3 | $11M | Buy |
399,048
+42,324
| +12% | +$1.25M | 0.01% | 1545 |
|
|
2019
Q2 | $11.8M | Buy |
356,724
+26,687
| +8% | +$914K | 0.01% | 1490 |
|
|
2019
Q1 | $11.6M | Buy |
330,037
+12,349
| +4% | +$459K | 0.01% | 1495 |
|
|
2018
Q4 | $10.6M | Buy |
317,688
+6,089
| +2% | +$262K | 0.01% | 1425 |
|
|
2018
Q3 | $15.7M | Buy |
311,599
+23,662
| +8% | +$1.17M | 0.01% | 1325 |
|
|
2018
Q2 | $17.2M | Sell |
287,937
-28,509
| -9% | -$1.48M | 0.01% | 1201 |
|
|
2018
Q1 | $14.5M | Buy |
316,446
+30,443
| +11% | +$1.27M | 0.01% | 1229 |
|
|
2017
Q4 | $11.4M | Buy |
286,003
+48,732
| +21% | +$1.93M | 0.01% | 1380 |
|
|
2017
Q3 | $9.49M | Buy |
237,271
+34,074
| +17% | +$1.47M | 0.01% | 1474 |
|
|
2017
Q2 | $8.76M | Buy |
203,197
+7,918
| +4% | +$282K | 0.01% | 1451 |
|
|
2017
Q1 | $6.11M | Buy |
195,279
+10,572
| +6% | +$283K | 0.01% | 1638 |
|
|
2016
Q4 | $4.66M | Sell |
184,707
-6,610
| -3% | -$148K | 0.01% | 1784 |
|
|
2016
Q3 | $4.73M | Buy |
191,317
+54,294
| +40% | +$1.23M | 0.01% | 1691 |
|
|
2016
Q2 | $2.79M | Buy |
137,023
+8,387
| +7% | +$149K | ﹤0.01% | 1912 |
|
|
2016
Q1 | $1.96M | Sell |
128,636
-184,455
| -59% | -$2.41M | ﹤0.01% | 2055 |
|
|
2015
Q4 | $4.21M | Sell |
313,091
-41,694
| -12% | -$645K | 0.01% | 1638 |
|
|
2015
Q3 | $4.98M | Buy |
354,785
+203,999
| +135% | +$3.79M | 0.01% | 1476 |
|
|
2015
Q2 | $2.56M | Buy |
150,786
+46,578
| +45% | +$663K | ﹤0.01% | 1961 |
|
|
2015
Q1 | $1.26M | Buy |
104,208
+38,539
| +59% | +$364K | ﹤0.01% | 2292 |
|
|
2014
Q4 | $546K | Buy |
65,669
+22,669
| +53% | +$190K | ﹤0.01% | 2589 |
|
|
2014
Q3 | $374K | Hold |
43,000
| – | – | ﹤0.01% | 2696 |
|
|
2014
Q2 | $471K | Buy |
43,000
+11,200
| +35% | +$99.8K | ﹤0.01% | 2649 |
|
|
2014
Q1 | $285K | Hold |
31,800
| – | – | ﹤0.01% | 2826 |
|
|
2013
Q4 | $240K | Hold |
31,800
| – | – | ﹤0.01% | 2900 |
|
|
2013
Q3 | $234K | Sell |
31,800
-7,909
| -20% | -$53.1K | ﹤0.01% | 2861 |
|
|
2013
Q2 | $255K | Buy |
+39,709
| New | +$234K | ﹤0.01% | 2794 |
|
Other funds holding SUPN
AC
NAMI
SIMG
Charles Schwab's SUPN Position: Q2 2026 in Review
Charles Schwab reduced its Supernus Pharmaceuticals (SUPN) stake by 0.34% in Q2 2026, selling an estimated $116K and leaving 703,552 shares worth $32.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1516.
Charles Schwab first reported a position in SUPN in Q2 2013 and has held it in 53 quarters since. The position peaked at $36.5M in Q1 2026. 333 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.
- Charles Schwab held 703,552 shares of Supernus Pharmaceuticals worth $32.7M as of Q2 2026.
- Charles Schwab sold 2,424 Supernus Pharmaceuticals shares in Q2 2026, an estimated $116K.
- Supernus Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1516 holding.
- Charles Schwab first reported a position in Supernus Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Charles Schwab's Supernus Pharmaceuticals position peaked at $36.5M in Q1 2026.
- 333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.